Zen Ahmad
Division of Pulmonology, Department of Internal Medicine, Faculty of Medicine, Universitas Sriwijaya/Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

Comparison of SARS-CoV2 IgG Antibody Levels in Health Workers with and without a History of COVID-19 Infection after Heterologous Vaccination at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia Ferda Puspalina; Nova Kurniati; Eddy Mart Salim; Yuniza; Zen Ahmad
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 6 No. 16 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v6i16.713

Abstract

Background: The COVID-19 pandemic, which has spread very quickly, has created crises in all aspects of life around the world. The administration of the COVID-19 heterologous vaccine in Indonesia is prioritized for high-risk groups, one of which is health workers. This study aimed to determine the comparison of quantitative IgG antibody levels for SARS CoV2 between health workers with and without a history of being infected with COVID-19 after heterology vaccination at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia. Methods: This study was a cross-sectional analytic observational study. A total of 64 subjects participated in this study. Data analysis was carried out with the help of SPSS software in univariate and bivariate. Results: SARS-CoV2 IgG antibody levels with and without a history of being infected with COVID-19 after heterologous vaccination did not find a significant difference in IgG levels between the two groups. However, the quantitative IgG levels of SARS-CoV2 in the infected history group were greater, namely 4834.25 AU/mL, compared to no history of COVID-19 infection of 3833.35 AU/mL Conclusion: There is a difference in the average SARS-CoV 2 IgG between subjects with a history of being infected with COVID-19 and without a history of COVID-19 at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia, although statistically, it is not significantly different.
Comparison of SARS-CoV2 IgG Antibody Levels in Health Workers with and without a History of COVID-19 Infection after Heterologous Vaccination at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia Ferda Puspalina; Nova Kurniati; Eddy Mart Salim; Yuniza; Zen Ahmad
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 6 No. 16 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v6i16.713

Abstract

Background: The COVID-19 pandemic, which has spread very quickly, has created crises in all aspects of life around the world. The administration of the COVID-19 heterologous vaccine in Indonesia is prioritized for high-risk groups, one of which is health workers. This study aimed to determine the comparison of quantitative IgG antibody levels for SARS CoV2 between health workers with and without a history of being infected with COVID-19 after heterology vaccination at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia. Methods: This study was a cross-sectional analytic observational study. A total of 64 subjects participated in this study. Data analysis was carried out with the help of SPSS software in univariate and bivariate. Results: SARS-CoV2 IgG antibody levels with and without a history of being infected with COVID-19 after heterologous vaccination did not find a significant difference in IgG levels between the two groups. However, the quantitative IgG levels of SARS-CoV2 in the infected history group were greater, namely 4834.25 AU/mL, compared to no history of COVID-19 infection of 3833.35 AU/mL Conclusion: There is a difference in the average SARS-CoV 2 IgG between subjects with a history of being infected with COVID-19 and without a history of COVID-19 at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia, although statistically, it is not significantly different.
Comparison of Post Vaccination Antibody Levels for Coronavirus Disease 2019 (COVID-19) between Survivors and Non-Survivors of COVID-19 Yuniza; Nova Kurniati; Zen Ahmad; Nurmalia Purnama Sari; Msy Rita Dewi
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 6 No. 17 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v6i17.729

Abstract

Background: The COVID-19 vaccine is useful for protecting the body by causing or stimulating specific immunity in the body. COVID-19 survivors are a group of individuals who have been exposed to COVID-19 and have successfully recovered from COVID-19 infection. Exposure to COVID-19 causes the activation of memory cells and anti-SARS-CoV-2 IgG antibodies. In contrast to individuals who have never been exposed to COVID-19, the bodies of individuals who are not COVID-19 survivors have not had the experience of exposure to COVID-19, which causes the absence of memory cells and anti-SARS-CoV-2 IgG antibodies. This study is one of the first studies to explore differences in anti-SARS-CoV-2 IgG antibody levels in survivors and non-survivors of COVID-19 at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia. Methods: This was an analytic observational study with a cohort approach. A total of 136 research subjects participated in this study. Observation of anti-SARS-CoV-2 IgG levels was carried out before vaccination, weeks 2, 12, and 24. Data analysis was carried out using SPSS univariate and bivariate. Results: The COVID-19 survivors group consistently from the time they were vaccinated, weeks 2, 12, and 24 showed a relatively higher average anti-SARS-CoV-2 IgG level than the non-COVID-19 survivors' group. The group of survivors of COVID-19 shows a trend of decreasing average anti-SARS-CoV-2 IgG levels over time. In contrast to the non-survivor group of COVID-19, which showed a trend of increasing anti-SARS-CoV-2 IgG levels. Conclusion: There were differences in anti-SARS-CoV-2 IgG levels between the COVID-19 survivor group and non-survivor COVID-19 group at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia.
Comparison of Post Vaccination Antibody Levels for Coronavirus Disease 2019 (COVID-19) between Survivors and Non-Survivors of COVID-19 Yuniza; Nova Kurniati; Zen Ahmad; Nurmalia Purnama Sari; Msy Rita Dewi
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 6 No. 17 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v6i17.729

Abstract

Background: The COVID-19 vaccine is useful for protecting the body by causing or stimulating specific immunity in the body. COVID-19 survivors are a group of individuals who have been exposed to COVID-19 and have successfully recovered from COVID-19 infection. Exposure to COVID-19 causes the activation of memory cells and anti-SARS-CoV-2 IgG antibodies. In contrast to individuals who have never been exposed to COVID-19, the bodies of individuals who are not COVID-19 survivors have not had the experience of exposure to COVID-19, which causes the absence of memory cells and anti-SARS-CoV-2 IgG antibodies. This study is one of the first studies to explore differences in anti-SARS-CoV-2 IgG antibody levels in survivors and non-survivors of COVID-19 at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia. Methods: This was an analytic observational study with a cohort approach. A total of 136 research subjects participated in this study. Observation of anti-SARS-CoV-2 IgG levels was carried out before vaccination, weeks 2, 12, and 24. Data analysis was carried out using SPSS univariate and bivariate. Results: The COVID-19 survivors group consistently from the time they were vaccinated, weeks 2, 12, and 24 showed a relatively higher average anti-SARS-CoV-2 IgG level than the non-COVID-19 survivors' group. The group of survivors of COVID-19 shows a trend of decreasing average anti-SARS-CoV-2 IgG levels over time. In contrast to the non-survivor group of COVID-19, which showed a trend of increasing anti-SARS-CoV-2 IgG levels. Conclusion: There were differences in anti-SARS-CoV-2 IgG levels between the COVID-19 survivor group and non-survivor COVID-19 group at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia.